Sale

Gene Therapy Market

Global Gene Therapy Market Size, Share, Growth, Trends: By Therapy Type: In-Vivo Therapy, Ex-Vivo Therapy; By Indications: Acute Lymphoblastic Leukemia (ALL), Inherited Retinal Disease, Large B-Cell Lymphoma, ADA-SCID, Melanoma, Beta-Thalassemia Major/SCD, Others; By Vector Type; Regional Analysis; Supplier Landscape; 2024-2032

Global Gene Therapy Market Outlook

The gene therapy market size attained a value of USD 7.81 billion in 2023. The market is anticipated to grow at a CAGR of 22.8% during the forecast period of 2024-2032 to attain a value of USD 49.60 billion by 2032. The growth of the market is driven by increased funding and investments.

 

gene therapy market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

The gene therapy market share is growing, supported by the increasing competition among major firms concentrating on the commercialisation of gene therapies, as well as the expansion of the field of advanced therapeutics and gene delivery technologies. Investments in acquisitions, mergers, and expansions are major methods used by biotechnology companies to strengthen their product pipelines and increase knowledge.

 

Also, increased funding and investments are anticipated to open up profitable growth potential for market participants in gene therapy. Recent years have seen a significant increase in the gene therapy market mainly due to the rapid technological advances in cellular and molecular biology and genomics research.

 

The gene therapy market growth is anticipated to be boosted throughout the forecast period by a strong gene therapy pipeline. Researchers are working to make gene therapies accessible in clinics. A wide range of products can be seen in the pipeline at various universities and institutes, which is projected to increase revenue generation in the near future.

 

Increasing Applications of Viral Vectors in Gene Therapy for the Treatment of Chronic Diseases Driving the Market Growth

The increasing applications of viral vectors in gene therapy for the treatment of neurological, metabolic, and neurodegeneration diseases are driving the segment growth. According to the gene therapy market report, viral vectors offer various favourable properties such as safety, low-toxicity, and excellent stability, due to which they are increasingly preferred in gene therapy. As adenoviruses have excellent DNA harbouring capacity, they are one of the most extensively applied viral vectors in gene therapy. They are also used for the development of vaccines and cancer therapies, hence fuelling the growth of the gene therapy market.

 

As per the gene therapy market forecast, viral vectors account for a significant share in the clinical trials of gene therapy owing to their efficiency to deliver genes to the target tissues/cells. The increasing regulatory approvals of gene therapy drugs based on viral vectors are further propelling the market. Over the forecast period, the emergence of Adeno-associated virus vectors (AAV) as a gene therapy platform for the treatment of neurological diseases is likely to propel the growth of the gene therapy global market.

 

North America Accounts for a Significant Share in the Market for Gene Therapy

The gene therapy market in North America is being driven by the growing healthcare expenditure in the region and a strong foothold of major biopharmaceutical companies focused on advancing gene therapy techniques. According to the gene therapy market research, the growing prevalence of health issues such as cancer and cystic fibrosis in the region is further propelling the demand for gene therapy. In addition, the surging initiation of gene therapy clinical trials in the region to develop effective treatments for chronic diseases is augmenting the market. Moreover, the introduction of various favourable initiatives by various governments to encourage innovations and advancements in gene therapy is likely to propel the market expansion. The surging approval rates of new gene therapies by regulatory authorities to expand therapeutic treatment choices are expected to further aid the cell and gene therapy market growth in the forecast period.

 

Market Segmentation

Gene therapy is defined as a medical approach that targets the genetic problem of a patient in order to treat or prevent diseases. In this treatment therapy, a person’s genetic make-up is altered or modified instead of using drugs or surgery. Several mechanisms, including the replacement of disease-causing genes, inactivation of a disease-causing gene, and introduction of a modified gene into the body, among others, are involved in this process.

 

gene therapy market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Based on indication, the market can be segmented into:

  • Neurological Disorder
  • Oncological Disorders
  • Rare Diseases
  • Eye Disorders
  • Others

 

By vector, the market is divided into:

  • Non-Viral Vector
  • Oligonucleotides
  • Others
  • Viral Vector
  • Retroviral Vectors
  • Adeno-associated Viral Vectors
  • Others

 

The EMR report looks into the regional markets of gene therapy like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

gene therapy market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Emergence of Gene Therapy as a Promising Treatment Option for Various Diseases to Boost the Market Growth

The emergence of gene therapy techniques as a promising treatment option for various genetic diseases such as muscular dystrophy and cystic fibrosis, among others, is increasing the gene therapy market size. The emerging treatment modalities, such as immunotherapy and oncolytic virotherapy, are increasingly gaining traction in cancer treatments. In addition to this, the increasing prevalence of cancer, coupled with the robust research and development activities aimed at expanding cancer treatment options, is likely to accelerate the growth of the cancer gene therapy market in the coming years. As cancer treatment options based on gene therapy offer a high success rate and enhanced flexibility, the market is expected to witness a healthy growth.

 

According to the gene therapy market analysis, gene therapy offers possibilities of positive medical outcomes and can create permanent results, which is strengthening the market growth. Over the forecast period, the increasing approvals of various gene therapy medications by regulatory authorities like the Food and Drug Administration (FDA) of the United States are expected to bolster the gene therapies market growth. Moreover, the evolving patient preference toward minimally invasive treatment procedures for diseases like lymphoma and leukaemia, among others, is anticipated to propel the gene therapy market growth in the coming years.

 

Key Players in the Global Market for Gene Therapy

The report gives a detailed analysis of the following key players in the global gene therapy market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

 

  • Novartis AG
  • Amgen Inc.
  • bluebird bio, Inc.
  • Biogen Inc.
  • Sibiono GeneTech Co. Ltd.
  • Gilead Sciences, Inc.
  • Sangamo Therapeutics, Inc.
  • Intellia Therapeutics, Inc.
  • REGENXBIO Inc.
  • Abeona Therapeutics Inc.
  • Orchard Therapeutics plc
  • Sio Gene Therapies Ltd.
  • Ultragenyx Pharmaceutical Inc.
  • Krystal Biotech, Inc.
  • Rocket Pharmaceuticals, Ltd.
  • MeiraGTx Limited.
  • Solid Biosciences Inc.
  • GenSight Biologics S.A.
  • Editas Medicine, Inc.
  • CRISPR Therapeutics AG
  • Spark Therapeutics, Inc.
  • Genprex, Inc.
  • Poseida Therapeutics, Inc.
  • Astellas Pharma Inc.
  • Voyager Therapeutics, Inc.
  • Coave Therapeutics
  • Precision BioSciences, Inc.
  • Others

 

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Therapy Type
  • Indications
  • Vector Type
  • Region
Breakup by Therapy Type
  • In-Vivo Therapy
  • Ex-Vivo Therapy
Breakup by Indications
  • Acute Lymphoblastic Leukemia (ALL)
  • Inherited Retinal Disease
  • Large B-Cell Lymphoma
  • ADA-SCID
  • Melanoma
  • Beta-Thalassemia Major/SCD
  • Head & Neck Squamous Cell Carcinoma
  • Peripheral Arterial Disease
  • Spinal Muscular Atrophy (SMA)
  • Others
Breakup by Vector Type
  • Viral Vector
  • Non-Viral Vector
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • CHIESI Farmaceutici SpA
  • Sunovion Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd
  • Mylan N.V., Orion Corporation
  • Merck & Co., Inc.
  • Grifols, S.A.
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • Vectura Group plc
  • Pfizer Inc, Alkermes
  • Mylan N.V, Almirall, S.A, Genentech, Inc
  • Biogen
  • Astellas Pharma Inc.
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology 
2    Executive Summary
3    Global Gene Therapy Market Overview
 
    3.1    Global Gene Therapy Market Historical Value (2017-2023) 
    3.2    Global Gene Therapy Market Forecast Value (2024-2032)
4    Global Gene Therapy Market Landscape
    4.1    Global Gene Therapy Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Gene Therapy Product Landscape
        4.2.1    Analysis by Therapy Type
        4.2.2    Analysis by Vector Type
        4.2.3    Analysis by Indications
5    Global Gene Therapy Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Gene Therapy Market Segmentation
    6.1    lobal Gene Therapy Market by Therapy Type
        6.1.1    Market Overview
        6.1.2    In-Vivo Therapy
        6.1.3    Ex-Vivo Therapy
    6.2    Global Gene Therapy Market by Indications
        6.2.1    Market Overview
        6.2.2    Acute Lymphoblastic Leukemia (ALL)
        6.2.3    Inherited Retinal Disease
        6.2.4    Large B-Cell Lymphoma
        6.2.5    ADA-SCID
        6.2.6    Melanoma
        6.2.7    Beta-Thalassemia Major/SCD
        6.2.8    Head & Neck Squamous Cell Carcinoma
        6.2.9    Peripheral Arterial Disease
        6.2.10    Spinal Muscular Atrophy (SMA)
        6.2.11    Others
    6.3    Global Gene Therapy Market by Vector Type
        6.3.1    Market Overview
        6.3.2    Viral Vector
            6.3.2.1    Lentiviral Vectors
            6.3.2.2    Adeno-Associated Viral (Aav) Vectors
            6.3.2.3    Retrovirus Vectors
            6.3.2.4    Modified Herpes Simplex Virus
            6.3.2.5    Adenovirus Vectors
            6.3.2.6    Others
        6.3.3    Non-Viral Vector
    6.4    Global Gene Therapy Market by Region
        6.4.1    Market Overview
        6.4.2    North America 
        6.4.3    Europe
        6.4.4    Asia Pacific
        6.4.5    Latin America
        6.4.6    Middle East and Africa
7    North America Gene Therapy Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Gene Therapy Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Gene Therapy Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Gene Therapy Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Gene Therapy Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by Year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Clinical Trials Analysis
    14.1     Analysis by Trial Registration Year 
    14.2    Analysis by Trial Status 
    14.3    Analysis by Trial Phase 
    14.4    Analysis by Therapeutic Area 
    14.5    Analysis by Geography 
15    Funding Analysis
    15.1    Analysis by Type of Funding
    15.2    Analysis by Funding Amount
    15.3    Analysis by Leading Players
    15.4    Analysis by Leading Investors
    15.5    Analysis by Geography
16    Partnership and Collaborations Analysis
    16.1    Analysis by Partnership Instances
    16.2    Analysis by Type of Partnership
    16.3    Analysis by Leading Players
    16.4    Analysis by Geography
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Supplier Landscape
    18.1    AstraZeneca
        18.1.1    Financial Analysis
        18.1.2    Product Portfolio
        18.1.3    Demographic Reach and Achievements
        18.1.4    Mergers and Acquisitions
        18.1.5    Certifications
    18.2    Boehringer Ingelheim International GmbH
        18.2.1    Financial Analysis
        18.2.2    Product Portfolio
        18.2.3    Demographic Reach and Achievements
        18.2.4    Mergers and Acquisitions
        18.2.5    Certifications
    18.3    GlaxoSmithKline plc
        18.3.1    Financial Analysis
        18.3.2    Product Portfolio
        18.3.3    Demographic Reach and Achievements
        18.3.4    Mergers and Acquisitions
        18.3.5    Certifications
    18.4    Novartis AG
        18.4.1    Financial Analysis
        18.4.2    Product Portfolio
        18.4.3    Demographic Reach and Achievements
        18.4.4    Mergers and Acquisitions
        18.4.5    Certifications
    18.5    CHIESI Farmaceutici SpA
        18.5.1    Financial Analysis
        18.5.2    Product Portfolio
        18.5.3    Demographic Reach and Achievements
        18.5.4    Mergers and Acquisitions
        18.5.5    Certifications
    18.6    Sunovion Pharmaceuticals Inc
        18.6.1    Financial Analysis
        18.6.2    Product Portfolio
        18.6.3    Demographic Reach and Achievements
        18.6.4    Mergers and Acquisitions
        18.6.5    Certifications
    18.7    Teva Pharmaceutical Industries Ltd
        18.7.1    Financial Analysis
        18.7.2    Product Portfolio
        18.7.3    Demographic Reach and Achievements
        18.7.4    Mergers and Acquisitions
    18.8    Mylan N.V., Orion Corporation
        18.8.1    Financial Analysis
        18.8.2    Product Portfolio
        18.8.3    Demographic Reach and Achievements
        18.8.4    Mergers and Acquisitions
        18.8.5    Certifications
    18.9    Merck & Co., Inc.
        18.9.1    Financial Analysis
        18.9.2    Product Portfolio
        18.9.3    Demographic Reach and Achievements
        18.9.4    Mergers and Acquisitions
        18.9.5    Certifications
    18.10    Grifols, S.A.
        18.10.1    Financial Analysis
        18.10.2    Product Portfolio
        18.10.3    Demographic Reach and Achievements
        18.10.4    Mergers and Acquisitions
        18.10.5    Certifications
    18.11    Abbott
        18.11.1    Financial Analysis
        18.11.2    Product Portfolio
        18.11.3    Demographic Reach and Achievements
        18.11.4    Mergers and Acquisitions
        18.11.5    Certifications
    18.12    F. Hoffmann-La Roche Ltd
        18.12.1    Financial Analysis
        18.12.2    Product Portfolio
        18.12.3    Demographic Reach and Achievements
        18.12.4    Mergers and Acquisitions
        18.12.5    Certifications
    18.13    Vectura Group plc
        18.13.1    Financial Analysis
        18.13.2    Product Portfolio
        18.13.3    Demographic Reach and Achievements
        18.13.4    Mergers and Acquisitions
        18.13.5    Certifications
    18.14    Pfizer Inc, Alkermes
        18.14.1    Financial Analysis
        18.14.2    Product Portfolio
        18.14.3    Demographic Reach and Achievements
        18.14.4    Mergers and Acquisitions
        18.14.5    Certifications
    18.15    Mylan N.V, Almirall, S.A, Genentech, Inc
        18.15.1    Financial Analysis
        18.15.2    Product Portfolio
        18.15.3    Demographic Reach and Achievements
        18.15.4    Mergers and Acquisitions
        18.15.5    Certifications
    18.16    Biogen
        18.16.1    Financial Analysis
        18.16.2    Product Portfolio
        18.16.3    Demographic Reach and Achievements
        18.16.4    Mergers and Acquisitions
        18.16.5    Certifications
    18.17    Astellas Pharma Inc.
        18.17.1    Financial Analysis
        18.17.2    Product Portfolio
        18.17.3    Demographic Reach and Achievements
        18.17.4    Mergers and Acquisitions
        18.17.5    Certifications
19    Global Gene Therapy Market- Distribution Model (Additional Insight)
    19.1    Overview 
    19.2    Potential Distributors 
    19.3    Key Parameters for Distribution Partner Assessment
20    Key Opinion Leaders (KOL) Insights (Additional Insight)
21    Company Competitiveness Analysis (Additional Insight)

    21.1    Very Small Companies
    21.2    Small Companies
    21.3    Mid-Sized Companies
    21.4    Large Companies
    21.5    Very Large Companies 
22    Payment Methods (Additional Insight)
    22.1    Government Funded
    22.2    Private Insurance
    22.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The global gene therapy market was valued at USD 7.81 billion in 2023.

The market is expected to grow at a CAGR of 22.8% from 2024 to 2032 to reach a value of USD 49.60 billion by 2032.

The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The major drivers of the market include the increasing prevalence of chronic diseases, the growing approvals of gene therapy medications by health authorities, and the increasing inclination towards minimally invasive treatment procedures.

The growing research and development (R&D) activities by the major biopharmaceutical companies to expand gene therapy treatment options, the surging prevalence of cancer, and the growing initiation of gene therapy clinical trials.

Neurological disorder, oncological disorders, rare diseases, and eye disorders, among others, are the different indication segments of gene therapy.

Non-viral vector and viral vector are the significant vectors of gene therapy in the market.

The major players in the market are Novartis AG, Amgen Inc., bluebird bio, Inc., Biogen Inc., Sibiono GeneTech Co. Ltd., Gilead Sciences, Inc., Sangamo Therapeutics, Inc., Intellia Therapeutics, Inc., REGENXBIO Inc., Abeona Therapeutics Inc., Orchard Therapeutics plc, Sio Gene Therapies Ltd., Ultragenyx Pharmaceutical Inc., Krystal Biotech, Inc., Rocket Pharmaceuticals, Ltd., MeiraGTx Limited., Solid Biosciences Inc., GenSight Biologics S.A., Editas Medicine, Inc., CRISPR Therapeutics AG, Spark Therapeutics, Inc., Genprex, Inc., Poseida Therapeutics, Inc., Astellas Pharma Inc., Voyager Therapeutics, Inc., Coave Therapeutics, and Precision BioSciences, Inc., among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER